 Kintara Therapeutics NASDAQ:KTRA Inc announced its first international site activation in its Global Coalition for Adaptive Research GCAR registrational Phase 23 clinical trial for glioblastoma multiforme GBM. The treatment arm was activated in Canada at Torontos Sunnybrook Health Sciences Centre. 